238 related articles for article (PubMed ID: 23566419)
1. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
Brandão RD; Veeck J; Van de Vijver KK; Lindsey P; de Vries B; van Elssen CH; Blok MJ; Keymeulen K; Ayoubi T; Smeets HJ; Tjan-Heijnen VC; Hupperets PS
Breast Cancer Res; 2013 Apr; 15(2):R29. PubMed ID: 23566419
[TBL] [Abstract][Full Text] [Related]
2. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.
Litviakov NV; Cherdyntseva NV; Tsyganov MM; Slonimskaya EM; Ibragimova MK; Kazantseva PV; Kzhyshkowska J; Choinzonov EL
Oncotarget; 2016 Feb; 7(7):7829-41. PubMed ID: 26799285
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Lustberg MB; Povoski SP; Zhao W; Ziegler RM; Sugimoto Y; Ruppert AS; Lehman AM; Shiels DR; Mrozek E; Ramaswamy B; Layman RM; Brueggemeier RW; Shapiro CL
Clin Breast Cancer; 2011 Aug; 11(4):221-7. PubMed ID: 21729671
[TBL] [Abstract][Full Text] [Related]
4. A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer.
Sooriakumaran P; Macanas-Pirard P; Bucca G; Henderson A; Langley SE; Laing RW; Smith CP; Laing EE; Coley HM
Cancer Genomics Proteomics; 2009; 6(2):93-9. PubMed ID: 19451093
[TBL] [Abstract][Full Text] [Related]
5. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
6. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
Martin LA; Davies GL; Weigel MT; Betambeau N; Hills MJ; Salter J; Walsh G; A'Hern R; Dowsett M
Breast Cancer Res Treat; 2010 Oct; 123(3):829-36. PubMed ID: 20697803
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.
Tuynman JB; Buskens CJ; Kemper K; ten Kate FJ; Offerhaus GJ; Richel DJ; van Lanschot JJ
Ann Surg; 2005 Dec; 242(6):840-9, discussion 849-50. PubMed ID: 16327494
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib treatment alters the gene expression profile of normal colonic mucosa.
Glebov OK; Rodriguez LM; Lynch P; Patterson S; Lynch H; Nakahara K; Jenkins J; Cliatt J; Humbyrd CJ; Denobile J; Soballe P; Gallinger S; Buchbinder A; Gordon G; Hawk E; Kirsch IR
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1382-91. PubMed ID: 16835340
[TBL] [Abstract][Full Text] [Related]
9. Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Chow LW; Loo WT; Wai CC; Lui EL; Zhu L; Toi M
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S298-301. PubMed ID: 16507397
[TBL] [Abstract][Full Text] [Related]
10. Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
Wolf B; Goebel G; Hackl H; Fiegl H
BMC Cancer; 2016 Oct; 16(1):821. PubMed ID: 27770790
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients.
Zhao Y; Wang Y; Zhu F; Zhang J; Ma X; Zhang D
Clin Exp Med; 2020 May; 20(2):249-259. PubMed ID: 31980982
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy with celecoxib to women with early stage breast cancer.
Tfayli A; Yang J; Kojouri K; Kesserwan C; Jafari M; Ozer H
Neoplasma; 2008; 55(2):122-6. PubMed ID: 18237249
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
[TBL] [Abstract][Full Text] [Related]
15. The role of COX-2 inhibition in breast cancer treatment and prevention.
Arun B; Goss P
Semin Oncol; 2004 Apr; 31(2 Suppl 7):22-9. PubMed ID: 15179621
[TBL] [Abstract][Full Text] [Related]
16. Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.
Assefnia S; Dakshanamurthy S; Guidry Auvil JM; Hampel C; Anastasiadis PZ; Kallakury B; Uren A; Foley DW; Brown ML; Shapiro L; Brenner M; Haigh D; Byers SW
Oncotarget; 2014 Mar; 5(6):1458-74. PubMed ID: 24681547
[TBL] [Abstract][Full Text] [Related]
17. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s).
Narayanan BA; Condon MS; Bosland MC; Narayanan NK; Reddy BS
Clin Cancer Res; 2003 Aug; 9(9):3503-13. PubMed ID: 12960143
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer chemoprevention with celecoxib in former smokers.
Mao JT; Roth MD; Fishbein MC; Aberle DR; Zhang ZF; Rao JY; Tashkin DP; Goodglick L; Holmes EC; Cameron RB; Dubinett SM; Elashoff R; Szabo E; Elashoff D
Cancer Prev Res (Phila); 2011 Jul; 4(7):984-93. PubMed ID: 21733822
[TBL] [Abstract][Full Text] [Related]
20. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Phillips RK; Wallace MH; Lynch PM; Hawk E; Gordon GB; Saunders BP; Wakabayashi N; Shen Y; Zimmerman S; Godio L; Rodrigues-Bigas M; Su LK; Sherman J; Kelloff G; Levin B; Steinbach G;
Gut; 2002 Jun; 50(6):857-60. PubMed ID: 12010890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
